Looks like the analysts picked up on the language as well:

BMO Capital Markets' Alex Arfaei also said the release's wording suggests the study results "may not be very clinically meaningful" and "may not justify the safety issues." However, Arfaei noted that expectations for the drug are "very low" and maintained his outperform rating on the stock. "We believe the franchise could reach global sales of $1.5-2Bn," he said.